GlobeNewswire

AroCell utökar med en Regulatory Affairs Director

Dela

AroCell AB (publ.) tillkännager i dag att Peter Löwendahl ingår i ledningsgruppen som Senior Director Regulatory Affairs. Peter Löwendahl kommer att leda och utveckla AroCells regulatoriska strategi med fokus på den amerikanska marknaden och FDA-godkännande av vår TK 210 ELISA.

Peter Löwendahl har 30 års erfarenhet av kvalitet och regulatory affairs och har tidigare varit koncernansvarig för Kvalitet och Regulatory affairs på Elekta AB och Globalt regulatory ansvarig för GE Healthcares Life science division. Sedan tre år tillbaka jobbar han i huvudsak som senior konsult och rådgivare för Hoff & Lowendahl AB.

"Jag är väldigt glad över att vi attraherat Peter som ansvarig för Arocells regulatoriska strategi. AroCell är i en spännande fas på väg in på den amerikanska marknaden och den regulatoriska inriktningen är en viktig del av detta", säger Michael Brobjer, VD på AroCell. "Peters långa erfarenhet av att placera medicintekniska produkter på den amerikanska marknaden gör mig övertygad om att han kommer att tillföra kunskap och erfarenhet till företaget."

"Jag ser fram emot att arbeta med AroCell och deras biomarkörs analys. Jag är imponerad av vad ett litet team kan åstadkomma och ivriga att vara en del av det”, säger Peter Löwendahl.

För ytterligare information:
Michael Brobjer, VD
Telefon: +46(0)18 50 30 20
E-post: michael.brobjer@arocell.com

 

Informationen lämnades, genom Michael Brobjers försorg, för offentliggörande den 11 september 2019 kl.14.00.

Kort om AroCell

AroCell AB (AROC) är ett svenskt bolag som utvecklar standardiserade moderna blodtest för att stödja behandling, prognos och uppföljning av cancerpatienter. AroCells teknik är baserad på patenterade metoder för att mäta proteinkoncentrationen av Tymidinkinas 1 (TK1) i blodprov. TK 210 ELISA-testet ger värdefull information som kommer att kunna hjälpa kliniker att optimera behandlingsstrategier och prognostisera risken för återkommande tumörsjukdom vid monitorering och uppföljning av patienten. AroCell (AROC) är listat på Nasdaq First North Growth Market med Redeye AB som Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90.
För mer information, se www.arocell.com


Bilaga

Om

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

EVS Broadcast Equipment reports update of share buyback program20.1.2020 18:00:00 CETPress release

Publication on January 20, 2020, 6.00pm CET Regulated information – reporting share buyback EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS reports update of share buyback program EVS Broadcast Equipment reports that the following transactions, conducted within the framework of the share buyback program announced on October 24, 2018, took place between January 14, 2020 and January 17, 2020. Date Number of shares acquired Average price (EUR) Total (EUR) 14/01/2020 1,000 21.1750 21,175 15/01/2020 500 21.1250 10,563 16/01/2020 750 21.0833 15,812 17/01/2020 500 21.1000 10,550 As of January 17, 2020, and since the start of the buyback program, EVS has bought 324,282 shares at an average price of EUR 20,9751, representing in total EUR 6,801,832. After aforementioned transactions the total number of own shares amounts now to 402,930 shares as of January 17, 2020 (including 93,144 shares already held by the company before the start of the sha

NNIT A/S: 1/2020 NNIT releases preliminary figures for 2019 and outlook for 202020.1.2020 17:09:00 CETPress release

Company announcement 01/2020 NNIT releases preliminary figures for 2019 and preliminary guidance for 2020 In connection with reporting the collected consensus information back to analysts, the preliminary, unaudited figures were unfortunately disclosed by a mistake. Please find further information below. Revenue increase of 1.7% and an operating profit margin of 7.8% before restructuring costs (8.0% in constant currencies) in 2019. Performance highlights for the fourth quarter of 2019 and guidance: Revenue decreased by 2.7% in Q4 2019 compared to Q4 2018 driven by a 27% decline from the Novo Nordisk Group. This was partly countered by growth from international life sciences (35%), finance (24%), public (18%) and Danish life sciences (5.9%) Excluding business from Novo Nordisk Group revenue increased 13% (8.4% organic) in Q4 2019. The share of NNIT’s revenue from clients outside the Novo Nordisk Group increased to 70% in Q4 2019 from 61% in Q4 2018 Gross profit decreased by 13% in Q4 20

Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease20.1.2020 15:32:00 CETPress release

Mayzent® (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe1 Mayzent addresses an unmet need for SPMS patients with active disease who, until now, did not have an oral treatment that has been shown to be effective in delaying progression in this patient population Approval is based on the Phase III EXPAND trial, the largest randomized clinical study in a broad range of SPMS patients, showing Mayzent significantly reduced the risk of disease progression, including physical disability and cognitive decline2,3 The digital press release with multimedia content can be accessed here: https://novartis.gcs-web.com/Novartis-announces-EU-approval-of-Mayzent-siponimod-for-adult-patients-with-secondary-progressive-multiple-sclerosis-SPMS-with-active-disease Basel, January 20, 2020 — Novartis today announced the European Commission (EC) has approved Mayzent® (siponimod) for the treat

Stolt-Nielsen Limited Presentation and Conference Call for the Fourth Quarter and Full Year of 2019 Results20.1.2020 14:00:00 CETPress release

LONDON, January 20, 2020 – Stolt-Nielsen Limited (Oslo Børs: SNI) will hold a presentation and conference call to discuss the Company’s unaudited results for the fourth quarter and full year of 2019 on Thursday, January 30, 2020 at 13:00 CET (07:00 EDT, 12:00 BST) in the auditorium at Swedbank, Filipstad Brygge 1, 0115 Oslo, Norway. The presentation and call will be hosted by: - Mr. Niels G. Stolt-Nielsen - Chief Executive Officer, Stolt-Nielsen Limited - Mr. Jens F. Grüner-Hegge - Chief Financial Officer, Stolt-Nielsen Limited Those who wish to participate may dial in local numbers +44 (0) 8445718892 in the UK, +47 2396 0264 in Norway, and +1 6315107495 in the US or the international number +44 (0) 2071 928000 and quote the conference code: 7375857. Phone lines will open 10 minutes before the call. A live audio webcast of the presentation may be accessed via the Stolt-Nielsen website at: https://www.stolt-nielsen.com/en/investors/reports-presentations/ For additional information pleas

Valmet receives the best A rating in CDP's climate program ranking for the second consecutive year20.1.2020 10:00:00 CETPress release

Valmet Oyj's press release on January 20, 2020 at 11:00 a.m. EET Valmet has been recognized for its actions and strategy to mitigate climate change by receiving the best A rating in CDP's climate program ranking for the second consecutive year. CDP's evaluation is based on the company's 2019 disclosure about its actions in the last reporting year to develop the low-carbon technology and solutions, cut emissions and mitigate climate risks. Valmet has a systematic program to reduce CO2 emissions in its own operations with a focus on more sustainable transportation, energy-efficiency improvements and process optimization. Valmet is actively developing new ways to improve energy, water and material efficiency and reduction of emissions of its solutions during customer use phase and to bring new innovations to the market. “We are proud to receive this recognition for our continuous work to contribute to the climate change mitigation. CO2 emissions need to be reduced rapidly in the coming ye